What George Clinical does

Emerald Clinical Trials (formerly George Clinical) is a Singapore-headquartered, full-service global contract research organization that has operated for more than 25 years. The company runs Phase I–IV and real-world clinical studies for pharmaceutical and biotechnology sponsors, organized around three flagship therapeutic areas — renal (its world-leading specialty with 100+ studies across 70+ countries), oncology (106,000+ participants enrolled across 2,200+ sites), and cardiovascular — together with adjacent cardiometabolic and early-phase work. Service modules span Early Phase Studies, Clinical Trial Management (study design and start-up, patient recruitment, project management, risk-based monitoring, endpoint adjudication), Safety & Pharmacovigilance, Regulatory Consulting, Medical Writing, and Data Management & Biostatistics. Core technology is a clinical trial management platform supporting Phase I–IV and real-world studies, with risk-based monitoring and automation in pharmacovigilance cited as proprietary feature areas.

The business model is professional services delivered on a project-based, quote-priced, multi-year contract basis to enterprise pharmaceutical buyers and biotech sponsors; pricing is not publicly disclosed and is set by scope, therapeutic complexity, phase, and geography. Go-to-market is consultative enterprise field sales — direct engagement via 'Request a proposal' CTAs — augmented by scientific thought leadership (KOL spotlights, webinars, content marketing), industry-conference presence (SOHO, BioJapan, ERA, ASCO, Obesity Science & Innovation, Precision in Clinical Trials Summit), and social channels including LinkedIn, X, Facebook, and WeChat. Emerald claims relationships with 15 of the world's top 20 pharmaceutical firms and 160+ biotech companies, delivered through in-country teams across Singapore, Australia, New Zealand, the Philippines, India, Malaysia, South Korea, China, the UK, the US, and broader EMEA. The company rebranded from George Clinical to Emerald Clinical Trials and underwent a CEO transition in July 2025 when Glenn Kerkhof was appointed interim CEO.

Name

George Clinical

Legal name

Emerald Clinical Trials

Website

https://georgeclinical.com

Company type

Private

Operating status

Operating

Short description

Emerald Clinical Trials (formerly George Clinical) is a Singapore-headquartered full-service global CRO that runs Phase I–IV and real-world trials for pharma and biotech sponsors, with world-leading renal expertise alongside oncology and cardiovascular capabilities.

Ownership category

akta.pro rank

Product category

Contract Research Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Contract research organization
• Clinical trial management
• Pharmacovigilance services
• Renal clinical research
• Oncology clinical trials

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices12 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: Full-service CRO providing end-to-end clinical trial solutions including trial management, regulatory consulting, safety services, medical writing, and data management. Revenue is generated through project-based service contracts with biotech and pharmaceutical sponsors across all phases of clinical development.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Emerald Clinical Trials (formerly George Clinical) is a full-service global contract research organization (CRO) providing end-to-end clinical trial solutions across all phases (Phase I-IV and real-world studies) for biotech and pharmaceutical sponsors. Core therapeutic franchises are Renal, Oncology, and Cardiovascular, supplemented by service modules including Early Phase Studies, Clinical Trial Management, Safety & Pharmacovigilance, Regulatory Consulting, Medical Writing, and Data Management & Biostatistics.

Product overview

Emerald Clinical Trials (formerly George Clinical) is a full-service global clinical research organization (CRO) providing end-to-end clinical trial solutions across all phases (Phase I-IV and real-world studies). The company's platform centers on three core therapeutic areas—Renal (their flagship expertise with 100+ studies across 70+ countries), Oncology (with 2,200+ sites and 106,000+ participants enrolled), and Cardiovascular—supplemented by comprehensive service modules including Early Phase Studies, Clinical Trial Management (with sub-services for study design, patient recruitment, project management, monitoring, and endpoint adjudication), Safety & Pharmacovigilance, Regulatory Consulting, Medical Writing, and Data Management & Biostatistics. The offering combines scientific leadership with operational excellence from an Asia-Pacific base, extending services globally through teams in China, EMEA, and the Americas.

Differentiator

Problem solved

Functional benefit

Products and services

• Early Phase Studies Phase I clinical trial services providing foundational safety and dosing data for drug development programs, anchored by Australian early-phase capabilities.
• Clinical Trial Management End-to-end trial management encompassing study design and start-up, patient recruitment, project management, risk-based clinical trial monitoring, and endpoint adjudication across global trial sites.
• Safety & Pharmacovigilance Services Comprehensive safety surveillance with seamless monitoring throughout the product lifecycle, backed by 20+ years of experience and advanced automation for flexible global compliance solutions.
• Regulatory Consulting Regulatory strategy and consulting services tailoring approaches to client needs, streamlining clinical trial execution from start-up through safety reporting.
• Medical Writing Professional medical writing services supporting clinical documentation throughout the drug development lifecycle.
• Data Management & Biostatistics Comprehensive clinical data management and biostatistics services ensuring data quality, integrity, and regulatory compliance.
• Renal Research World-leading renal research expertise with over 100 renal studies conducted across 70+ countries, guided by the world's foremost renal experts with proven operational excellence and high recruitment rates.
• Oncology Research Global oncology trial expertise with over 106,000 participants enrolled across 2,200+ sites worldwide, spanning Australian Early Phase to global Phase III trials with oncology-specialized teams.
• Cardiovascular Research Cardiovascular trial services with comprehensive end-to-end capabilities, guided by multidisciplinary clinician and researcher KOLs and informed by deep regional insights across global populations.
• Accelerated Oncology Proof-of-Concept Specialized oncology service designed to accelerate proof-of-concept milestones through adaptive trial design and rapid execution strategies.
• Real-World Studies Real-world evidence studies complementing traditional clinical trial data with post-market surveillance and observational research capabilities.

Quantifiable outcome

• Consistently high recruitment and retention rates
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Key Opinion Leaders (KOLs) and Investigators NetworkcoreOthersEmerald Clinical partners with top investigators and KOL networks globally to drive faster, smarter development in renal, oncology, cardiometabolic, and early-phase research. These relationships enable access to leading clinical researchers and facilitate study design and execution.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Syneos Health: Privately held global full-service CRO and commercialization provider across clinical development and post-approval services. Competes across Phase I-IV with both pharma and biotech sponsors.
• ICON plc: Top-3 global CRO post-PRA Health acquisition, offering full-service clinical development with strong biotech and pharma sponsor rosters. Competes for Phase II–IV and biotech CRO work globally.
• IQVIA: World's largest CRO with end-to-end Phase I-IV capabilities, deep technology/data platforms, and global infrastructure across all major therapeutic areas. Competes with Emerald for enterprise pharma RFPs and mega-deals.
• Parexel International: Privately held global full-service CRO (owned by EQT/Goldman Sachs) competing for Phase I-IV trials and biotech/pharma enterprise sponsors. Comparable in offering breadth and therapeutic expertise.
• Labcorp (Covance Clinical Trials): Major global clinical trials and diagnostics provider through Covance, with broad Phase I-IV capabilities and deep pharma/biotech relationships. Competes for full-service enterprise CRO contracts.

Direct peers

• Medpace: Mid-sized, US-headquartered full-service CRO specializing in small-to-mid biotech sponsors with therapeutic-area depth in oncology, cardiovascular, and metabolic disease. Most directly comparable peer in business model and sponsor segment.
• PSI CRO: Privately held mid-sized full-service CRO with strong therapeutic expertise and a global footprint focused on biotech and mid-sized pharma. Comparable in scale, therapeutic depth, and operational model.
• Worldwide Clinical Trials: Mid-sized, scientifically-led global CRO focused on complex therapeutic areas including oncology and cardiometabolic disease, serving mid-sized pharma and biotech. Closely comparable in scale, model, and therapeutic positioning.
• Novotech: Asia-Pacific-headquartered, mid-sized full-service CRO focused on biotech clinical trials across multiple therapeutic areas. Direct competitor for APAC-anchored biotech sponsors and overlapping therapeutic expertise in oncology.

Regional players

• Tigermed (Hangzhou Tigermed): China's largest domestic CRO providing full-service clinical trial services across all phases. Regional peer competing primarily in China and APAC biotech sponsor segments that overlap with Emerald's footprint.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/emeraldclinical
• Facebookfacebook.com/emeraldclinical
• LinkedInlinkedin.com/company/emeraldclinical

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about George Clinical